Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation

AIMS: We compared the 1‐year safety and effectiveness of dabigatran 110 mg (D110) or 150 mg (D150) twice daily to vitamin K antagonists (VKA) in patients with nonvalvular atrial fibrillation. METHODS: New user cohort study of patients dispensed D110 or D150 vs. VKA in 2013 for nonvalvular atrial fib...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Blin, Patrick, Dureau‐Pournin, Caroline, Cottin, Yves, Bénichou, Jacques, Mismetti, Patrick, Abouelfath, Abdelilah, Lassalle, Regis, Droz, Cécile, Moore, Nicholas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6339969/
https://ncbi.nlm.nih.gov/pubmed/30423205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13815
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller